

***In vitro* investigation of the individual contributions of **ultrasound-induced** stable and inertial cavitation in targeted drug delivery**

Dana Gourevich^{a,b}, Alexander Volovick^{a,c}, Osnat Dogadkin^{a,c}, , Lijun Wang^a, Helen Mulvana^d
Yoav Medan^e, Andreas Melzer^a and Sandy Cochran^{a,*}

^aInstitute for Medical Science and Technology, University of Dundee, Dundee, UK

^bCapsutech Ltd, Nazareth, Israel

^cInSightec Ltd, Haifa, Israel

^dUniversity of Glasgow, Glasgow, UK

^eTechnion, Haifa, Israel

*Corresponding Author:

Sandy Cochran,

Professor of Biophysical Science and Engineering,

Institute for Medical Science and Technology,

School of Medicine,

University of Dundee,

1 Wurzburg Loan,

Dundee, DD2 1FD, UK

s.cochran@dundee.ac.uk

1 **Abstract**

2 Ultrasound-mediated targeted drug delivery (UmTDD) is a therapeutic modality under
3 development, with potential to treat cancer. Its ability to produce local hyperthermia and cell
4 poration through cavitation non-invasively makes it a candidate to trigger drug delivery.
5 Hyperthermia offers greater potential for control, particularly with magnetic resonance imaging
6 (MRI) temperature measurement. However, cavitation may offer reduced treatment times, with real-
7 time measurement of ultrasonic spectra indicating drug dose and treatment success. Here, a clinical
8 MRI-guided focused ultrasound surgery (MRgFUS) system was used to study UmTDD *in vitro*.
9 Drug uptake into breast cancer cells in the vicinity of ultrasound contrast agent was correlated with
10 occurrence and quantity of stable and inertial cavitation, classified according to sub-harmonic
11 spectra. During stable cavitation, intracellular drug uptake increased by a factor up to 3.2 compared
12 to the control. This paper demonstrates the value of cavitation monitoring with a clinical system,
13 and its subsequent employment for dose optimisation.

14

15 Keywords: Targeted Drug Delivery, Focused Ultrasound, Microbubbles, Cancer cell, Cavitation,
16 Subharmonic, **Ultrasound contrast agent.**

17

18 **Introduction**

19 Hypertthermia and cavitation are the ultrasound-related mechanisms that have been reported to
20 cause increased intracellular drug uptake (Böhmer et al. 2009; Liu et al. 2001; Wu and Nyborg
21 2008; Gourevich et al. 2013). The term ‘cavitation’ describes two different physical processes,
22 stable and inertial, with the latter sometimes termed ‘transient’ cavitation, that affect cells in
23 different ways. Whilst evidence exists that both types of cavitation can be utilised in ultrasound-
24 mediated targeted drug delivery (UmTDD) (Sundaram et al. 2003; Schlicher et al. 2006; Karshafian
25 et al. 2009), the literature provides conflicting information on which method may yield the most
26 effective results under a given set of experimental conditions (Fan et al. 2013; Domenici et al.
27 2013).

28 Stable and inertial cavitation have been shown to have different acoustic signatures, based on their
29 differing underlying physics and the mechanical index (MI) of the ultrasound from which they
30 originate (Leighton 1997; Brennen 1995). During stable cavitation, the bubbles oscillate, changing
31 size and sometimes shape. These oscillations are associated with the phenomenon of
32 microstreaming (Wu and Nyborg 2008) and can be detected by characteristic scattering of the
33 applied ultrasound. In the frequency domain, the detected ultrasound depends on the type of
34 oscillation (de Jong et al. 2009) and consists of harmonics, subharmonics and ultra-harmonics of the
35 fundamental driving ultrasound frequency. The scattered acoustic signal acquired during
36 sonoporation occurring as a result of inertial cavitation (Frenkel 2008) also has a characteristic
37 signature in the frequency domain, in this case broadband. Passive detection of scattered acoustic
38 emissions acquired during therapeutic ultrasound **has** been used to predict efficacy thresholds for
39 ablation (Jensen et al. 2013), and explored as a means to investigate exploitable conditions for
40 sonoporation (Fan et al. 2014; Somaglino et al. 2011; Chen et al. 2003; Hallow et al. 2006) e.g. by
41 using the sub-harmonic spectrum amplitude as an indication of sonoporation occurrence (Hensel et
42 al. 2009). Thus further insight into the mechanisms responsible for biological effects related to
43 UmTDD can be gained through defining and correlating the types of cavitation generated with

44 transfection and cell viability results (Bazan-Peregrino et al 2012; Gao et al, 2008; Fan 2031;
45 Hassan 2010).

46 An additional major concern regarding UmTDD *in vitro* is the ability to differentiate cavitation
47 effects from those correlated with increased temperature and verification that any heating produced
48 unavoidably does not contribute to the observed biological effects. In this context, in the work
49 presented here the experimental environment was based on a clinical magnetic resonance imaging
50 guided focused ultrasound surgery (MRgFUS) system which allowed differentiation between the
51 heating and cavitation mechanisms associated with ultrasound application. This system was
52 characterized to gain understanding of the physical properties affecting the outcomes of cell culture
53 experiments, and hence aid in overcoming difficulties in reproducibility of results in *in vitro*
54 UmTDD experiments as has been raised previously by different authors (ter Haar et al. 2011;
55 Hassan et al. 2010; Hensel et al. 2011; Kinoshita 2007; Leskinen and Hynynen, 2012).

56 Following arduous and lengthy experimental work *in vitro* and *in vivo* (Chen et al. 2010),
57 therapeutic ultrasound is becoming an established clinical modality used mainly for tissue ablation,
58 hyperthermia, and lithotripsy (Crouzet al. 2010; Lafon et al. 2002; ter Haar 1995; Barnett et al.
59 1994; Jolesz 2009). However, notwithstanding the work of others (Bazan-Peregrino et al 2012;
60 Razavi et al. 2014), cavitation-based UmTDD is not yet sufficiently developed for clinical
61 application and development is still under way, as required for tumour treatment, of techniques to
62 monitor cavitation and to determine how cavitation may be used to predict resultant drug dose. This
63 paper aims to contribute new knowledge on optimized values and conditions relating to use of
64 cavitation in UmTDD to assist in development of this important therapeutic modality.

65 **Materials and Methods**

66 *Experimental Apparatus and Setup*

67 An ExAblate 2000 system (InSightec, Tirat Carmel, Israel) was used as the sonication platform in
68 the described *in vitro* study. The source of ultrasound in this system is a concave phased array with
69 26 annuli each divided into eight sectors to give a total of 208 transmitting ultrasonic array elements

70 organised in 26 transducer rings (Tr), The radius of curvature is 160 mm, aperture 120 mm, and the
71 operating frequencies can be set in the range of 0.95 - 1.35 MHz. Quasi-continuous excitation is
72 used, making the bandwidth extremely small for any given frequency. The array elements can be
73 turned on and off individually and also allow phase adjustment with 45° quantisation. An additional
74 complete concave element with radius 11.5 mm acts as a receiver, located coaxially with the
75 transmitting array to allow spectral responses to be recorded. Signals are acquired from the
76 receiving element for 150 ms every 200 ms, using a low-pass filter with a cut-off frequency of
77 approximately 700 kHz to reduce the amplitude of the transmitted signal. After each acquisition, the
78 signal is subjected to a fast Fourier transform (FFT) and the frequency domain result is recorded.

79 The ExAblate 2000 system complies with international HITU standards - IEC62555 (HITU
80 radiation force) and IEC62556 (HITU field characterization) as well as IEC60601 (“Medical
81 electrical equipment: Particular requirements for the basic safety and essential performance of high
82 intensity therapeutic ultrasound (HITU) equipment”), and is calibrated accordingly. In addition, it
83 was tested prior to each set of sonications, using the same method as for its clinical application, i.e.
84 by sonication of a specially manufactured daily quality assurance (DQA) phantom which verified
85 the dimensions of the focal zone as well as its delivery to a specified location.

86 Ninety six-well polystyrene μ -clear plates with a 0.2 mm thick base (Greiner Bio-One, Stonehouse,
87 UK) were found to be the best cell culture environment, with manageable heat effects and space to
88 fit the focal spot within the 7 mm diameter and 10 mm depth of each well. Titer-Tops sealing film
89 (EMS, Hatfield, PA, USA) with a thickness of 0.1 mm was used to seal the open tops of the wells to
90 maintain the sterility of the cells’ microenvironment and to reduce acoustic boundary interface
91 effects by allowing complete plate immersion in water.

92 To ensure that the wells did not behave as ultrasonic waveguides during sonication (Sommer et al.
93 1997, Redwood 1960), which would shift focal point toward the distal end of the well, we reduced
94 the focal zone diameter which excited different propagation modes, allowing ultrasound
95 propagation in the well not as a plane wave but with some interference between the modes (Figure

96 1A). This indicated there is a trade-off between the spot size and waveguide effects when sonicating
97 an inverted 96-well plate using focused ultrasound.

98 In order to validate the optimal parameters for sonication inside a well, acoustic field measurements
99 were performed as described below. The full experimental setup is depicted in Figure 1B and Figure
100 1C shows the order in which the wells were sonicated. To reduce secondary effects caused by
101 accumulated dissipation of acoustic power in neighbouring wells, the sonicated wells were
102 separated by wells with various contents (e.g. with microbubbles (MBs), without MBs and empty).
103 The sonication order was also set in such a way as to avoid sonicating two neighbouring wells one
104 after another and to minimize time-related effects on MBs by sonicating wells containing MBs first,
105 as shown in Figure 1C. The 96-well plate was placed 92 mm above the transducer.

106 *Acoustic and Thermal Evaluation*

107 To estimate acoustic power loss and unwanted heat distribution, a separate base portion of a 96-well
108 plate, supplied by the manufacturer, and the Titer-Tops sealing film were mounted in a special
109 frame and scanned acoustically. To determine how much of the acoustic power was dissipated
110 during the sonication, we utilised externally gated, pulsed sonications, each only a few seconds
111 long, using the ExAblate transducer as the ultrasound source. A 0.5 mm polyvinylidene difluoride
112 (PVDF) needle hydrophone (Precision Acoustics, Dorchester, UK) was placed in the focal plane of
113 the transducer to record the waves. Acoustic scanning equipment described previously (Gourevich
114 et al. 2013) was used to scan a 2D plane and the amplitude of the ultrasonic wave-front through a
115 focal plane was recorded in water and with the base and sealing parts of the 96-well plate immersed
116 between the transducer and the hydrophone.

117 The relatively small well diameter of 96-well plates means that care must be taken when they are
118 used in ultrasound-related *in vitro* experiments. To determine suitability, detect possible limitations,
119 and identify an appropriate sonication pattern, i.e. the focal distance (FD) and the form of the beam,
120 two sets of experiments were done. First, successively increasing proportions (20%, 50% then
121 100%) of the array elements from the centre outwards were activated coherently to narrow the focal

122 width increasingly, while leaving the remaining elements inactive. Second, increasing proportions
123 (0%, 50% then 100%) of the array elements were excited with random phases to determine the
124 effect of coherence. As detailed in the Results, the most appropriate activation of those investigated
125 was determined to be of the central 50% of the array elements (13 annuli) with coherent excitation.

126 An additional issue that may influence the focal behaviour is the FD inside a well. Because of the
127 plate geometry, as stated above, various disruptions can occur during the passage of the beam
128 through the well. To establish the optimal height for sonication inside a single well within a plate,
129 which will yield minimal distribution of power to the neighbouring wells, and to evaluate the
130 influence of a sonication on neighbouring wells, acoustic field measurements were performed over
131 an inverted plate at different focal points. The hydrophone in these measurements was less than 1
132 mm from the surface of the inverted plate, bringing it into close proximity with the theoretical cell
133 location.

134 To differentiate between the thermal and mechanical effects that are associated with application of
135 ultrasound, thermal measurements were made with an infrared (IR) thermal imaging camera (FLIR
136 Systems CeDIP JADE camera, Kent, UK). A 96-well plate was only partly immersed in water, to
137 overcome the opacity of water to IR wavelengths. The plate was sonicated at room temperature
138 (RT) using different acoustic power levels for 90 s each, allowing cooling time between the
139 sonications.

140 *Cavitation Spectrum Measurements*

141 The definition of cavitation dose, CD, used here is based on an approach in which, for each time
142 acquisition, the magnitude of the signal in the frequency domain is integrated around the
143 subharmonic frequency, $f = 0.475 \pm 0.1$ MHz, and these values are further integrated for the whole
144 period of the sonication, as defined in Equation 1 (Hallow et al. 2006).

$$145 \quad CD = \sum_t \int_{0.375}^{0.575} a(f) df \quad (1)$$

146 This definition allows a distinction between experiments in which there is no cavitation and those
147 with stable and inertial cavitation, where lower values of CD indicate no cavitation and larger

148 values indicate stable and then inertial cavitation. The fundamental unit of CD in this scheme is
149 mV.

150 Figure 2 shows three examples of possible cavitation spectrum readings, as recorded by the
151 ExAblate 2000 during ultrasonic exposure of cells within treatment groups containing MB, (A)
152 showing no cavitation; (B) showing a single subharmonic peak from non-linear stable cavitation;
153 and (C) showing broadband noise from inertial cavitation. Linear cavitation was not studied during
154 this research.

155 *Cell Maintenance*

156 Cultures of MCF-7 human breast cancer cells (American Type Culture Collection (ATCC),
157 Manassas, Virginia, USA) were grown as monolayers on 75 cm² cell culture flasks (TPP Techno
158 Plastic Products AG, Trasadingen, Switzerland) in Complete Medium (CM) i.e. Dulbecco's
159 Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1%
160 penicillin streptomycin (5000 I.U./ml, 5000 lg/ml; Gibco Invitrogen, Paisley, UK). They were kept
161 in humidified air with 5% CO₂ at 37°C. Re-seeding of the cells was performed twice each week
162 using Trypsin-ethylenediaminetetraacetic acid (EDTA) 0.05% (Gibco Invitrogen, Paisley, UK).

163 For UmTDD studies, 15,000 cells/well were seeded in 100 µL CM, in µ-clear 96-well plates
164 (Greiner Bio-One, Stonehouse, UK) three days in advance, in order to reach confluence on the day
165 of the experiment. Prior to the application of ultrasound, the CM in the wells was replaced with the
166 following solutions:

- 167 • *Uptake studies* - Treatment group: 25 µM doxorubicin (Dox) (Discovery, Wimborne, UK) in
168 CM with 0.025% dimethyl sulfoxide (DMSO) and 4.7% of ultrasound contrast agent (USCA)
169 Sonovue solution, i.e. 4 x 10⁶ MBs per well (Bracco Research SA, Milan, Italy); Control:
170 Dox in CM with 0.025% DMSO.
- 171 • *Viability assessment* - Treatment group: CM with MB at the same concentration, i.e. 4 x 10⁶
172 MBs per well; Control: CM only.

173 • *Membrane Permeability assessment* - Treatment group: CM with MB at the same
174 concentration, i.e. 4×10^6 MBs per well; Control: CM only.

175 In all the experiments, the Sonovue MBs were prepared according to the manufacturer's
176 instructions and kept in an ice bath throughout the experiment, except when in use. The MBs were
177 added to the final Dox/CM solution in individual portions per plate and the final solutions were
178 applied immediately to the cell monolayers.

179 The uptake of Dox into the MCF-7 cell line was investigated using fluorescence intensity
180 measurement (Infinite M200, Tecan Group, Mannedorf, Germany) with excitation and emission
181 wavelengths of 485 nm and 592 nm, respectively. Following ultrasound treatment, it was observed
182 that some cells detached from the mono-layer. This detachment was attributed to ultrasound
183 application and extensive cell washing to remove excess Dox left between the cells. As the detached
184 cells were discarded during the washes, they did not contribute to the total fluorescence reading.
185 Therefore we correlated the uptake, as indicated by the fluorescence measurements, with the
186 number of viable cells. This was achieved by normalization of the fluorescence readings by the total
187 protein amount present within each well after ultrasound exposure, using the bicinchoninic acid
188 (BCA) assay (Smith et al. 1985). The recorded protein amounts following sonication were also
189 compared to the control groups to estimate the level of cell loss due to the different treatments.

190 The viability of cells after ultrasound exposure was quantified by MTT (3-(4,5-Dimethylthiazol-2-
191 yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, Dorset, UK), a colorimetric assay which
192 correlates with cells' viability via their enzymatic activity (Cole 1986; Twentyman and Luscombe
193 1987). Additionally, a membrane integrity test (CytoTox-ONE, Promega, UK) was conducted to
194 quantify the level of membrane permeability due to ultrasound application (Cho et al. 2002). In the
195 presence of MBs, ultrasound is known to increase cell membrane permeability. Therefore,
196 measurement of lactate dehydrogenase (LDH) levels released from leaking membrane into the
197 media can indicate the level of membrane permeability achieved by sonication. The level of

198 resofurin, which is proportional to the amount of LDH, was measured by fluorescence intensity
199 measurements (Kaur et al 2007).

200 *Experimental Procedure and Ultrasound Application*

201 The solutions described above were added to each well, to a total volume of 420 μL , according to
202 the defined treatment groups (Figure 1C) and the plates were sealed using Titer-Tops (EMS,
203 Hatfield, PA, USA). The cells were sonicated continuously for 10 s with the following parameters;
204 acoustic power level, $P = 1 \text{ W}$, as the defined output of the ExAblate 2000 system which was
205 focused at the centre of each well in all axes (FD = 97 mm); peak negative pressure, PNP =
206 0.53 MPa; intensity, $I = 18.77 \text{ W/cm}^2$; mechanical index, $MI = 0.54$; and frequency, $f = 0.95 \text{ MHz}$.
207 The plate was placed inverted to ensure that the MBs were in proximity to the cell monolayer,
208 owing to MB buoyancy. The sonications were performed in the order shown in Figure 1C, such that
209 the wells containing the MBs were sonicated first.

210 Following the sonication process, the cells were washed twice with phosphate-buffered saline (PBS;
211 Oxoid, Basingstoke, UK). For the uptake studies, the cells were lysed with 0.5% sodium dodecyl
212 sulphate (SDS; Sigma-Aldrich, Dorset, UK) and the total fluorescence intensity of each well was
213 recorded and normalized by total protein count using the BCA method (Smith et al. 1985). The
214 cellular uptake of the sonicated samples was calculated as a percentage of the unsonicated samples,
215 i.e. the control group, which was seeded in the same 96-well plate:

$$216 \quad \text{Drug Uptake} = \frac{\left(\frac{\text{Dox Fluorescence [RFU]}_{\text{sample}}}{\text{Total Protein Amount } [\mu\text{g}]_{\text{sample}}} \right)}{\left(\frac{\text{Dox Fluorescence [RFU]}_{\text{control}}}{\text{Total Protein Amount } [\mu\text{g}]_{\text{control}}} \right)} \quad (2)$$

217 The cell loss in each well after sonication was established according to the BCA absorbance
218 readings relative to the control group, by:

$$219 \quad \text{Cell Loss} = \left(\frac{\text{Total Protein Amount } [\mu\text{g}]_{\text{sample}}}{\text{Total Protein Amount } [\mu\text{g}]_{\text{control}}} \right) \quad (3)$$

220 The viability studies were performed to determine if the sonication on its own, with and without
221 MBs, caused cell necrosis, regardless of the presence of Dox. For assessment of cell viability, the
222 same procedure was performed as in the uptake studies, where the indicated solutions were added to
10

223 the different groups and the cells were sonicated at the specified parameters. Following the
 224 sonication process, 100 μL of fresh CM was added after two washes with PBS, then the cell
 225 viability was either assessed immediately or cell recovery studies were performed. The latter
 226 included additional 24 h incubation at 37 $^{\circ}\text{C}$ in 5% CO_2 . The cell viability was assessed by addition
 227 of 20 μL of MTT and 3 h incubation at 37 $^{\circ}\text{C}$ in 5% CO_2 . The created formazan was dissolved in
 228 100 μL DMSO (Gibco Invitrogen, Paisley, UK), the plate was shaken for 50 s and the absorption
 229 signal at 550 nm was recorded with a plate reader (Infinite M200, Tecan Group Mannedorf,
 230 Germany). The level of cell viability was calculated relative to the control group of unsonicated
 231 cells:

$$232 \quad \text{Cell Viability} = \left(\frac{\text{MTT Absorbance}_{\text{sample}} - \text{Background}}{\text{MTT Absorbance}_{\text{control}} - \text{Background}} \right) \quad (4)$$

233 In the membrane permeability studies, the plate was centrifuged at 2000 rpm for 10 min to spin
 234 down any cells present in the medium following sonication. 50 μL of the medium in each well were
 235 transferred into a new black 96-well plate (Greiner Bio-One, Stonehouse, UK) and an equivalent
 236 amount of resazurin reagent was added. After an incubation period of 10 min at RT, the stop
 237 solution was added and the fluorescent signal was measured with an excitation wavelength of
 238 560 nm and emission wavelength of 590 nm. The fluorescence readings were normalized by the
 239 total protein amount using the BCA method as described above. The membrane permeability was
 240 calculated as follows:

$$241 \quad \text{Membrane Permeability} = \frac{\left(\frac{\text{LDH [RFU]}_{\text{sample}} - \text{Background}}{\text{Total Protein Amount } [\mu\text{g}]_{\text{sample}}} \right)}{\left(\frac{\text{LDH [RFU]}_{\text{control}} - \text{Background}}{\text{Total Protein Amount } [\mu\text{g}]_{\text{control}}} \right)} \quad (5)$$

242 All the ultrasound cell culture studies were performed in a water environment at 30 $^{\circ}\text{C}$, the upper
 243 temperature limit of the experimental setup.

244 For each plate, nine replicates were done for each treatment group and an additional six replicates
 245 for each type of control group. Throughout the various uptake, viability and membrane permeability
 246 experiments, each set of applied ultrasound parameters was replicated at least three times to ensure

247 statistically significant data collection and correlation with spectral recording. All the values in the
248 results section are presented with their standard deviations.

249 **Results**

250 *Characterisation of Setup*

251 In our experimental set up we found that the base of the μ -clear 96-well plate and the Titer-Tops
252 sealing caused minimal attenuation of the acoustic signals, with, on average, 95.7% and 99.8% of
253 the transmitted power passed through the base and the sealing, respectively (Figure 3A). Figure 3B
254 represents the acoustic measurements at different focal points performed at 50% Tr with **an acoustic**
255 **power of 1 W** at 0.95 MHz. The acoustic field measurements above the 96-well plate, showed that I
256 in neighbouring wells is less than 4% of the peak intensity of the targeted well, with the minimal I
257 distribution to the neighbouring wells being when the focus is in the middle of the well, i.e.
258 $FD = 97$ mm. The acoustic field measurements showed that changing the aperture of the transducer
259 by deactivating outer elements increased the focal length and diameter as expected, as well as
260 distorting the focal shape, **especially** at 20% Tr (Figure 3C). **Based on these measurements, the**
261 **aperture of the transducer to be applied was established as using half the transmitting elements**
262 **(50% Tr) and chosen such that the focal zone diameter entering the well was 2.6 mm.**

263 According to the results of the thermal camera measurements presented in Figure 4 for the chosen
264 ultrasound parameters, with **$P = 1$ W** for 10 s, the overall temperature rise was only 0.44°C
265 ($\pm 0.2^{\circ}\text{C}$).

266 *Biological Studies and Cavitation Spectrum Measurement*

267 Analysis of the relationship between the cell results and the cavitation spectrum measurements was
268 applied to two groups. The first group, represented by Figure 5, contains all the measurement points
269 **from all** the intracellular drug uptake and membrane permeability experiments. The second group,
270 represented by Table 1 and Figures 6 and 7, contains results averaged \pm SD in accordance with the
271 sonication order, i.e. time of sonication, presented in Figure 2B.

272 Figure 5A shows the dependence of intracellular drug uptake on the CD. There is a distinct
273 separation in outcome depending on the presence or absence of MBs. Without MBs, no significant
274 cavitation occurs, as is also evident in the uptake levels which are below a factor of 1.5 relative to
275 the control group. On the contrary, with MBs, the drug uptake varies by factors from 1.5 up to 3.2
276 with varying CD. Figure 5B depicts the correlation between the permeability of the cells'
277 membranes as a result of ultrasound application.

278 As can be seen in Figure 5B, there is a significant increase in the membrane permeability of the
279 cells, by a factor up to 3.5, in the presence of MBs, with an increasing trend with decreasing CD
280 values. Figure 5C shows the dependence of drug uptake on the cell loss, where a linear fitting
281 represents the relation between the uptake values and the number of cells missing from each well
282 after sonication and washing. According to this trend, higher levels of cell loss correspond to higher
283 uptake values, which can be explained by the fact that larger effects on the cell membrane cause
284 greater penetration of the cytotoxic drug into the cells. This is also evident from the linear
285 correlation between the uptake and the cell membrane permeability (Figure 5D).

286 Table 1 differentiates between stable and inertial cavitation for the different wells containing MB,
287 according to the order of sonication. The classification in Table 1 was performed according to the
288 maximum CD spectrum reading for each sonication; thus, if the sonication is classified as stable, it
289 is assumed that no inertial cavitation has taken place. From Table 1, it can be seen that the
290 occurrence of inertial cavitation decreases over time, corresponding to the order of sonication,
291 whilst stable cavitation occurs instead. Our results show that the recorded $CD = 0.22 \pm 0.06\text{mV}$ and
292 higher correspond to the occurrence of inertial cavitation, whereas $CD = 0.15 \pm 0.02\text{ mV}$ and lower
293 correlate with stable cavitation.

294 Figure 6 presents the dependence of the drug uptake, membrane permeability and CD on the time
295 passing after the first sonication. As previously mentioned, the treatment groups without MB were
296 sonicated last. It can be seen that sonications without the MBs produce consistent results both for
297 the intracellular drug uptake and membrane permeability, with up to 20% variation from the

298 average value: these results are not time dependent. On the other hand, sonications performed on
299 the wells with MBs manifest a bigger span of results and are time-dependent.

300 The dependence of immediate viability and cell recovery studies on the order of the sonications is
301 presented in Figure 7A and B, respectively. The trend-lines shown in Figures 6 and 7 are the linear
302 fitting representations of the dependence of the groups containing MBs on the order of sonication.

303 **Discussion**

304 This study was designed to define the individual contributions of stable and inertial cavitation to
305 intracellular uptake of a chemotherapeutic agent within cancer cells. The initial step was the
306 characterisation of the experimental arrangements including 96-well plates sonicated with a
307 clinically approved system. This has confirmed that the use of the standard cell culture environment
308 does not compromise the properties of the ultrasound propagation. Moreover, the acoustic energy
309 levels that were used do not cause significant thermal effects, allowing differentiation between
310 hyperthermia and cavitation.

311 Our Dox uptake results indicate a threshold between drug uptake and cavitation activity with and
312 without MBs. While there was no effect on either the uptake or the membrane permeability in the
313 absence of MBs, the intracellular drug uptake was, on average, increased by a factor of 2.14 ± 0.46
314 relative to the control group in the presence of MBs.

315 Membrane integrity tests were conducted to gain better understanding of the mechanism of uptake
316 enhancement by MBs in acoustic environment. The membrane integrity assay quantified the level
317 of LDH present in the media due to leaking cell membranes. Accordingly, it was possible to
318 evaluate the membrane permeability achieved by sonication. In this study we utilised a simple
319 fluorescence-based measurement technique to validate the mechanism of drug uptake into the cells.

320 **The close correlation between the increases in cellular uptake and the membrane permeability (i.e.**
321 **3.2 and 3.5 fold, respectively) indicate that membrane permeability studies involving quantification**
322 **of LDH levels can be used as a tool to establish the levels of membrane permeability caused by the**
323 **application of ultrasound.**

324 The average decrease in viability of cells immediately after sonication in the wells containing MBs
325 was recorded as $31\% \pm 8\%$ relative to the control group. Taken together with the 24 h recovery
326 studies, where the average decrease in the same group was $19\% \pm 5\%$, this indicates that some of
327 the cell damage caused by sonication was reversible and did not lead directly to cell death.

328 Therefore we conclude that there is an acoustic intensity window inside which the permeability of
329 the cell membranes increases due to the presence of ultrasound-driven MBs which allows greater
330 intracellular drug uptake, while permeabilisation is not permanent as it does not cause excessively
331 high levels of cell death.

332 The drug uptake dependence on cell loss along with the cell viability studies indicated that greater
333 cell loss is caused by the increased uptake of toxic drugs into the cells, rather than for any other
334 reason. The average results of the cell culture studies are in agreement with previously described
335 work by other authors using different experimental configurations (Pitt et al. 2004).

336 The dependence of drug uptake on CD indicates that greater uptake is achieved for smaller values
337 of CD, i.e. $0.12 \text{ mV} < \text{CD} < 0.19 \text{ mV}$, suggesting that stable, non-linear cavitation with a peak at $\frac{1}{2}$
338 the transmitting frequency is responsible for greater uptake and membrane permeability. Indeed,
339 sorting the results according to the order of the sonicated wells, we have found that inertial
340 cavitation occurred mainly within the first four sonicated wells, whereas stable cavitation was
341 detected mainly in the last three sonicated wells that contained MBs. From the representation of the
342 results as a function of time starting at the first sonication, there is a trend of increased drug uptake
343 and reduced CD. This suggests that the increased drug uptake into the cell monolayers in our
344 experiments was caused by stable, rather than inertial, cavitation. The dependence of the uptake on
345 cell loss shows that stable cavitation also caused a greater cell loss. This is also evident in the
346 immediate viability studies where there is a reduction in viability as a function of time similar to the
347 CD. Nonetheless, this trend is decreased in the 24 h recovery studies as shown by the fact that the
348 slope of the linear trend in the 24 h viability is half that generated from immediate viability studies.

349 We have calculated that the initial MB concentration was enough to cover the surface of the cells in
350 a single monolayer, yet not high enough to attenuate the ultrasound beam. Therefore, we
351 hypothesize that the initial inertial cavitation in our experiments, during the first three sonications,
352 was caused by destruction of MBs in their original form, being unstable due to their relatively large
353 diameters (e.g. $> 9 \mu\text{m}$). As, initially, the fraction of MBs in this range of diameters is significantly
354 smaller than for other diameters (Gorce et al. 2000), the impact of the inertial cavitation on cell loss,
355 viability and drug uptake is lower. After 100 s, the time between the first and the seventh
356 sonications, larger quantities of the MBs retained diameters of 8 - 9 μm due to their spontaneous
357 increase in diameter in a time dependent manner at temperature above RT (Guiot et al. 2006;
358 Mulvana et al. 2010, 2011; Vos et al. 2008). These MBs are more attuned to resonate at
359 $f = 0.95 \text{ MHz}$ (Gorce et al. 2000), the ultrasonic frequency in use, and hence a greater effect was
360 achieved due to the irregular oscillations associated with stable non-linear cavitation.

361 **Conclusions**

362 In this study, a clinically approved MRgFUS system was used for cell studies *in vitro*. Adaptation
363 of a clinical system in this way carries the potential for use of a single system from *in vitro* studies
364 through the pre-clinical stage to clinical trials. Moreover, a well-defined experimental setup that can
365 be used in a clinical environment promotes a reproducible baseline of *in vitro* and *in vivo* results,
366 which can promote related research, e.g. in conjugation with novel drug carriers (Wang and
367 Thanoua 2010), in multiple centres. The ability offered by this system to quantify cavitation dose
368 has the potential to explain previously obscure results. The method used for cavitation detection in
369 this study has advantages of robustness and simplicity. More precise cavitation detection methods
370 have been suggested by Gyongy and Coussios, 2010. The use of the passive cavitation detection
371 method they describe, along with the method described in our work, will allow better localization of
372 cavitation and correlation between the sub-harmonics and harmonics and the intracellular drug
373 uptake.

374 The absolute values of the drug uptake results presented here are in line with previously reported
375 work by other authors using different experimental configurations. Moreover, the spectral recording
376 that has been performed has allowed us to determine that the highest drug uptake was achieved in
377 the presence of stable, non-linear cavitation. According to our findings, there is higher uptake at
378 lower CD values. This is contradictory to the common assumption that UmTDD is governed by
379 inertial cavitation (Somaglino et al. 2011; Razavi et al. 2014). Here we have provided evidence that
380 stable cavitation with a lower CD, in the presence of MB, produces a greater impact on the
381 intracellular uptake. This should be taken into account in future cavitation related TDD studies.
382 Moreover, the hypothesis driven from our studies with Sonovue MB suggests that the time for
383 ultrasound application to the MB is crucial and should be carefully controlled and reported in the
384 literature.

385 **Acknowledgements**

386 The research leading to these results received funding from the European Community's Seventh
387 Framework Programme (FP7/2007-2013) under grant agreement 230674 (Nanoporation project).
388 The authors thank J. Grienfield, O. Prus and Y. Shafran of InSightec Ltd., J. Gnaim of Capsutech
389 Ltd., Fred Brewster of Greiner Bio-One, Rita Schmidt of Weissman Institute, Israel, P. Kozlovsky
390 of Tel Aviv University, Tel Aviv, Israel, and A. Gourevich, for their support and assistance.

391

392 **References**

- 393 Barnett, S., ter Haar, G., Ziskin, M., Nyborg, W., Maeda, K., BANG, J., 1994. Current status of
394 research on biophysical effects of ultrasound. *Ultrasound in Med & Biol* 20, 205 - 218.
- 395 Bazan-Peregrino, M., Arvanitis C.D., Rifai B., Seymour L.W., Coussios C-C.,2012. Ultrasound-
396 induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro
397 model. *Journal of Control Release* 157, 235 - 242.
- 398 Böhmer, M., Klibanov, A., Tiemann, K., Hall, C., Gruell, H., Steinbach, O., 2009. Ultrasound
399 triggered image-guided drug delivery. *European Journal of Radiology* 70, 242 - 253.
- 400 Brennen, C., 1995. *Cavitation and Bubble Dynamics*. Oxford University Press.
- 401 Chen, L., Mu, Z., Hachem, P., Ma, C.-M., Wallentine, A., Pollack, A., 2010. Mr-guided focused
402 ultrasound: enhancement of intratumoral uptake of [3h]-docetaxel in vivo. *Phys Med Biol.* 55, 7399
403 - 7410.
- 404 Chen, W.-S., Brayman, A., Matula, T., Crum, L., 2003. Inertial cavitation dose and hemolysis
405 produced in vitro with or without optison. *Ultrasound in Med & Biol* 29, 725 - 737.
- 406 Cho, C-W., Liu, Y., Cobb, W.N., Henthorn, T.K., Lillehei, K., Christians, U ., Ng, K-Y., 2000.
407 Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain
408 microvessel endothelial cells. *Pharmaceutical Research*, 19(8), 1123 - 1129.
- 409 Cole, S. P. C., 1986. Rapid chemosensitivity testing of human lung tumor cells using the mtt assay.
410 *Cancer Chemother Pharmacol* 17, 259 - 263.
- 411 Crouzet, S., Murat, F.J., Pasticier, G., Cassier, P., Chapelon, J.Y., Gelet, A., 2010. High intensity
412 focused ultrasound (HIFU) for prostate cancer: Current clinical status, outcomes and future
413 perspectives. *Int J Hyperthermia* 26(8), 796 - 803.
- 414 de Jong, N., Emmer, M., van Wamel, A., Versluis, M., 2009. Ultrasonic characterization of
415 ultrasound contrast agents. *Med Biol Eng Comput* 47, 861–873.

416 Domenici, F., Giliberti, C., Bedini, A., Palomba, R., Luongo, F., Sennato, S., Olmati, C., Pozzi, D.,
417 Morrone, S., Castellano, A.C., Bordi, F., 2013. Ultrasound well below the intensity threshold of
418 cavitation can promote efficient uptake of small drug model molecules in fibroblast cells. *Drug*
419 *Delivery* 20(7), 285 - 295.

420 Fan, Z., Chen, D., Deng, C.X., 2013. Improving ultrasound gene transfection efficiency by
421 controlling ultrasound excitation of microbubbles. *Journal of Control Release* 170(3), 401 - 413.

422 Fan, Z., Chen, D., Deng, C.X., 2014. Characterization of the dynamic activities of a population of
423 microbubbles driven by pulsed ultrasound exposure in sonoporation. *Ultrasound in Med & Biol* 40
424 (6), 1260 - 1272.

425 Frenkel, V., 2008. Ultrasound mediated delivery of drugs and genes to solid tumors. *Advanced*
426 *Drug Delivery Reviews* 60, 1193 - 1208.

427 Gao, Z., Kennedy, A., Christensen, D., Rapoport, N., 2008. Drug loaded nano/microbubbles for
428 combining ultrasonography and targeted chemotherapy. *Ultrasonics* 48, 260 - 270.

429 Gorce, J., Arditì, M., Schneider, M., 2000. Influence of bubble size distribution on the echogenicity
430 of ultrasound contrast agents a study of sonovue. *Investigative Radiology* 35, 661 - 671.

431 Gourevich, D., Dogadkin, O., Volovick, A., Wang, L., Gnaim, J., Cochran, S., Melzer, A., 2013.
432 Ultrasound mediated Targeted Drug Delivery with a Novel Cyclodextrin-based Drug Carrier by
433 Mechanical and Thermal Mechanisms. *Journal of Control Release* 170, 316 - 324.

434 Gourevich, D., Hertzberg, Y., Volovick, A., Shafran, Y., Navon, G., Cochran, S., Melzer, A., 2013.
435 Ultrasound-mediated targeted drug delivery generated by multifocal beam patterns: an in vitro
436 study. *Ultrasound in Med & Biol* 39, 507 - 514.

437 Guiot, C., Pastore, G., Napoleone, M., Gabriele, P., Trotta, M., Cavalli, R., 2006. Thermal response
438 of contrast agent microbubbles: Preliminary results from physico-chemical and US-imaging
439 characterization. *Ultrasonics* 44, e127 - e130.

440 Gyongy, M., Coussios, C., 2010. Passive spatial mapping of inertial cavitation during HIFU
441 exposure. *IEEE Transactions on biomedical engineering* 57, 423 - 56.

442 Hallow, D., Mahajan, A., McCutchen, T., Prausnitz, M., 2006. Measurement and correlation of
443 acoustic cavitation with cellular bioeffects. *Ultrasound in Med & Biol* 32, 1111 - 1122.

444 Hassan, M., Buldakov, M., Ogawa, R., Zhao, Q.-L., Furusawa, Y., Kudo, N., Kondo, T., Riesz, P.,
445 2010. Modulation control over ultrasound-mediated gene delivery: Evaluating the importance of
446 standing waves. *Journal of Controlled Release* 141, 70 - 76.

447 Hensel, K., Haagen, R., Schmitz, G., Maghnouj A., Hahn S.A., 2009. Evaluation of subharmonic
448 emission from encapsulated microbubbles as an indicator for sonoporation of cell monolayers.
449 *IEEE Int Ultrason Symp Proc* 1, 19 - 22.

450 Hensel, K., Mienkina, M., Schmitz, G., 2011. Analysis of ultrasound fields in cell culture wells for
451 in vitro ultrasound therapy experiments. *Ultrasound in Med & Biol* 37(12), 2105 - 2115.

452 Jensen, C.R., Cleveland, R.O., Coussios C.C., 2013. Real-time temperature estimation and
453 monitoring of HIFU ablation through a combined modeling and passive acoustic mapping
454 approach. *Phys Med Biol* 58, 5833 - 5850.

455 Jolesz, F., 2009. MRI-guided focused ultrasound surgery. *Annual Review of Medicine* 60, 417 -
456 430.

457 Kaur, P., Jodhka, PK. Underwood WA., Bowles CA, de Fiebre, Christopher NEC. de Fiebre M.,
458 and Singh M. 2007. Progesterone Increases Brain-Derived Neurotrophic Factor Expression and
459 Protects Against Glutamate Toxicity in a Mitogen-Activated Protein Kinase- and Phosphoinositide-
460 3 Kinase-Dependent Manner in Cerebral Cortical Explants. *Journal of Neuroscience Research*
461 85:2441–2449.

462 Karshafian, R., Bevan, P.D., Williams, R., Samac, S., Burns, P.N., 2009. Sonoporation by
463 ultrasound activated microbubble contrast agents: effects of acoustic exposure parameters on cell
464 membrane permeability and cell viability. *Ultrasound in Med & Biol* 35(5): 847-860.

465 Kinoshita, M., a. H. K., 2007. Key factors that affect sonoporation efficiency in in vitro settings:
466 The importance of standing wave in sonoporation. *Biochem Biophys Res Comm* 359, 860 - 865.

467 Lafon, C., Melo de Lima, D., Theille`re, Y., 2002. Optimizing the shape of ultrasound transducers
468 for interstitial thermal ablation. *Med Phys* 29(3), 290 - 297.

469 Lafon, C., Somaglino, L., Bouchoux, G., Mari, J.M., Chesnais, S., Ngo, J., Mestas, J-L., Fossheim,
470 S.L., Nilssen E.A., Chapelon, J-Y., 2012. Feasibility study of cavitation-induced liposomal
471 doxorubicin release in an AT2 Dunning rat tumor model. *Journal of Drug Targeting* 20(8), 691 -
472 702.

473 Leighton, T., 1997. *The Acoustic Bubble*. Academic Press.

474 Leskinen, J., Hynynen, K., 2012. Study of factors affecting the magnitude and nature of ultrasound
475 exposure with in vitro set-ups. *Ultrasound in Med & Biol* 38, 777 - 794.

476 Liu, Y., Cho, C.-W., Yan, X., Henthorn, T., Lillehei, K., Cobb, W., Ng, K., 2001. Ultrasound-
477 induced hyperthermia increases cellular uptake and cytotoxicity of p-glycoprotein substrates in
478 multi-drug resistant cells. *Pharmaceutical Research* 18, 1255 - 1261.

479 Mulvana, H., Stride, E., H. J., Eckersley, R., 2010. Temperature dependent behaviour of ultrasound
480 contrast agents. *Ultrasound in Med & Biol* 36, 925 - 934.

481 Mulvana, H., Stride, E., Tang, M., Hajnal, J., Eckersley, R., 2011. Temperature-dependent
482 differences in the nonlinear acoustic behaviour of ultrasound contrast agents revealed by high-speed
483 imaging and bulk acoustics. *Ultrasound in Med & Biol* 37, 1509 - 1517.

484 Pitt, W., Hussein, G., Staples, B. J., 2004. Ultrasonic drug delivery - a general review. *Exper Opin*
485 *Drug Deliv* 1, 37 - 56.

486 Razavi, A., Clement, D., Fowler, R.A., Birer, A., Chavrier, F.O., Mestas, J-L., Romano F.,
487 Chapelon, J-Y., Lafon C., 2014. Contribution of inertial cavitation in the enhancement of in vitro
488 transscleral drug delivery. *Ultrasound in Med & Biol*, 40(6), 1216 - 1227.

489 Redwood, M., 1960. *Mechanical Waveguides*. Pergamon, New York.

490 Schlicher, R., Radhakrishna, H., Tolentino, T., Apkarian, R., Zarnitsyn, V., Prausnitz, M., 2006.
491 Mechanism of intracellular delivery by acoustic cavitation. *Ultrasound in Med & Biol* 32, 915 -
492 924.

493 Smith, P., Krohn, R., Hermanson, G., Mallia, A., Gartner, F., Provenzano, M., Fujimoto, E., Goeke,
494 N., Olson, B., Klenk, D., 1985. Measurement of protein using bicinchoninic acid. *Analytical*
495 *Biochemistry* 19 (2570), 76 - 85, 3rd. edn.

496 Somaglino, L., Bouchoux, G., Mestas, J-L., Lafon C., 2011. Validation of an acoustic cavitation
497 dose with hydroxyl radical production generated by inertial cavitation in pulsed mode: Application
498 to in vitro drug release from liposomes. *Ultrasonics Sonochemistry* 18, 577 - 588.

499 Sommer, F., Sumanaweera, T., Glover, G., 1997. Tissue 474 ablation using an acoustic waveguide
500 for high-intensity focused ultrasound. *Medical Physics* 24 (4), 537 - 538.

501 Sundaram, J., Mellein, B., Mitragotri, S., 2003. An experimental and theoretical analysis of
502 ultrasound-induced permeabilization of cell membranes. *Biophysical Journal* 84, 3087 - 3101.

503 ter Haar, G., 1995. Ultrasound focal beam surgery. *Ultrasound in Medicine and Biology* 21, 1089 -
504 1100.

505 ter Haar, G., Shaw, A., Pye, S., Ward, B., Bottomley, F., Nolan, R., Coady, A.-M., 2011. Guidance
506 on reporting ultrasound exposure conditions for bio-effects studies. *Ultrasound in Med & Biol* 37,
507 177 - 183.

508 Twentyman, P., Luscombe, M., 1987. A study of some variables in a tetrazolium dye (mtt) based
509 assay for cell growth and chemosensitivity. *Br J Cancer* 56 (RAE-TR-71009), 279 - 285.

- 510 Vos, H.J., Dollet, B. Bosch, J.G., Versluis, M., De Jong, N., 2008. Nonspherical vibrations of
511 microbubbles in contact with a wall- a pilot study at low mechanical index. *Ultrasound in Med &*
512 *Biol* 34(4), 685 - 688.
- 513 Wang, M., Thanoua M. 2010. Targeting nanoparticles to cancer. *Pharmacological Research* 62, 90-
514 99.
- 515 Wu, J., Nyborg, W., 2008. Ultrasound, cavitation bubbles and their interaction with cells. *Advanced*
516 *Drug Delivery Reviews* 60, 1103 - 1116.
- 517

518 **List of Tables**

519 Table 1- Distribution of the stable and inertial cavitation during the uptake studies, between the ten
520 repetitions in each well with MBs in the plate. For example out of ten repetitions of the third
521 sonication, inertial cavitation occurred nine times and stable cavitation once. The order of the
522 sonications in the plate is shown in Figure 1C.

523

Sonication Order	1	2	3	4	5	6	7	8	9
<i>Time (s)</i>	<i>10</i>	<i>28</i>	<i>44</i>	<i>60</i>	<i>76</i>	<i>92</i>	<i>110</i>	<i>126</i>	<i>142</i>
Inertial Cavitation	9	8	9	9	4	5	1	2	1
Stable Cavitation	1	2	1	2	6	5	9	8	9

524